MediciNova Reports Results of a Phase IIb Trial of MN-221 in Asthma Exacerbations

MediciNova and the Jasdaq Market of the Osaka Securities Exchange, announced preliminary results from a hospital emergency department-based Phase IIb clinical trial evaluating MN-221 in patients with acute exacerbations of asthma did not statistically meet the primary endpoint, improvement in FEV1, or forced expiratory volume, in one second, compared to placebo.
RTT News